多发性骨髓瘤双抗原靶向T细胞免疫治疗:规避肿瘤异质性与防止抗原逃逸
靶向BCMA或GPRC5D的T细胞免疫治疗显著改善复发难治多发性骨髓瘤患者生存,但部分患者无应答且多数最终复发,肿瘤异质性和抗原逃逸是关键问题。同时靶向两种肿瘤相关抗原可能通过应对异质性靶表达和防止抗原逃逸提高疗效。多种双靶向策略正在评估中,包括两种单抗原靶向双特异性抗体的联合、三特异性抗体及双特异性CAR-T,但尚无明确优于单靶BCMA CAR-T的证据,需大规模3期试验与序贯单靶治疗比较。
要点
- 双抗原靶向可应对肿瘤异质性和抗原逃逸,是改善MM T细胞免疫治疗疗效的策略。
- teclistamab联合talquetamab在相似人群中抗MM活性优于相应常规BsAb单药。
- 双靶向CAR-T尚未显示明确优于ciltacabtagene autoleucel单靶BCMA。
核心结论
- 同时靶向两种肿瘤相关抗原可能通过应对异质性靶表达和防止抗原逃逸提高MM疗效。
- 双靶向策略需在大规模3期试验中与单靶药物序贯治疗伴靶点转换的经典方案比较。
研究设计与样本
- 综述性文章,汇总MM双抗原靶向T细胞免疫治疗的多种策略及研究证据。
主要发现
- 靶向BCMA或GPRC5D的T细胞免疫治疗显著改善复发难治MM患者生存,但部分患者无应答且多数最终复发。
- 肿瘤异质性导致抗原阴性及抗原低表达细胞快速选择,是影响单靶T细胞免疫治疗应答的关键问题。
- 抗原逃逸(缺失、突变或表观遗传改变)常见于CAR-T输注后进展或BsAb治疗期间。
- teclistamab联合talquetamab在相似患者人群中抗MM活性优于相应常规BsAb单药。
- 双抗原靶向三特异性抗体(如ramantamig [BCMA×GPRC5D]和ISB 2001 [BCMA×CD38])在重度经治MM中已显示有希望的结果。
关键数值与推荐
- 有限患者数研究显示,针对>1种抗原的CAR-T产品在晚期MM中有效。
- 目前尚无双靶向CAR-T产品显示明确优于ciltacabtagene autoleucel单靶BCMA。
临床怎么用
- 双抗原靶向策略可用于应对MM肿瘤异质性和抗原逃逸,包括BsAb联合、三特异性抗体和双靶CAR-T。
- 临床选择双靶向方案时需考虑现有证据尚未证明其优于单靶BCMA CAR-T,且需3期试验验证。
局限性
- 双靶向CAR-T证据来自有限患者数研究,尚未显示明确优于单靶BCMA CAR-T。
- 双靶向策略需大规模3期试验与序贯单靶治疗伴靶点转换比较,目前缺乏此类比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA)- or G protein-coupled receptor class C group 5 member D (GPRC5D)-directed T-cell immunotherapies have substantially improved the survival of patients with relapsed/refractory multiple myeloma (MM). Despite these advances, a subset of patients does not respond, and most patients will eventually relapse. Tumor heterogeneity, resulting in rapid selection of both antigen-negative and antigen-low cells, is a critical issue affecting response to T-cell immunotherapies targeting single tumor-associated antigens. In addition, antigen escape (due to deletions, mutations, or epigenetic alterations) is frequently observed in patients who experience disease progression after chimeric antigen receptor (CAR) T-cell infusion or during bispecific antibody (BsAb) treatment. Simultaneous targeting of 2 tumor-associated antigens may improve efficacy by addressing heterogeneous target expression and preventing antigen escape. Various dual-targeting strategies are currently evaluated in MM, including the combination of 2 single-antigen-targeting BsAbs. Of note, the efficacy of the combination of teclistamab and talquetamab appears to have enhanced anti-MM activity, compared with the corresponding conventional BsAbs alone in similar patient populations. Furthermore, dual-antigen targeting with T-cell-redirecting trispecific antibodies (eg, ramantamig [BCMA×GPRC5D] and ISB 2001 [BCMA×CD38]) has already demonstrated promising results in heavily pretreated MM. Studies with limited numbers of patients have demonstrated that CAR T-cell products with specificity for >1 antigen are also effective in advanced MM; however, at this time, none of the dual-targeting CAR T-cell products has been shown to be clearly superior to targeting BCMA alone with ciltacabtagene autoleucel. Dual targeting should eventually be compared in large phase 3 trials with the classical approach of serial treatment with monotargeting agents with target switch.
引用
- van de Donk NWCJ, Sonneveld P, Einsele H, et al. Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. Blood. 2026. PMID: 41610427. doi:10.1182/blood.2025032536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。